40.66
+0.67%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Xiangyu Medical Co
Its shares trade on Shanghai under the ticker 688626.SS. It has been listed since 31 March 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥767.7m and net income of CN¥78.7m. At that date it held total assets of CN¥3.27bn and shareholders' equity of CN¥2.04bn.
Xiangyu Medical Co., Ltd. engages in the development, procurement, production, and sale of rehabilitation medical equipment. The company is headquartered in Anyang, Henan. The company went IPO on 2021-03-31. The firm is mainly engaged in the independent research and development, production and marketing of intelligent rehabilitation equipment in the rehabilitation fields such as pain, neurology, orthopedics, traditional Chinese medicine, postpartum field, postoperative field, cardiopulmonary field, and medical-care integration. The firm's main products are divided into three categories: rehabilitation assessment, rehabilitation training, and rehabilitation physiotherapy. The firm mainly conducts business within the domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 31 Mar 2021
- Employees
- 1,703
- Website
- xyyl.com ↗
Leadership
Pay as last reported
- Mr. Yongzheng HeChairman of the Board, General Manager, since 2024
- Mr. Hongfeng JinChief Financial Officer
- Ms. Junling GuoDeputy General Manager, Secretary of the Board, Director, since 2016
- Mr. Junhai ShiDirector
- Mr. Zhen LiuIndependent Director
- Mr. Tiebin YanIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Xiangyu Medical's 1,703 employees support comprehensive rehabilitation equipment development and production.
- The company's focus on intelligent rehabilitation equipment covers pain, neurology, and orthopedics segments.
- Xiangyu Medical's domestic market presence ensures strong local market penetration and customer trust.
Weaknesses
- Limited international market presence restricts global revenue potential and brand recognition.
- The company's reliance on domestic market sales may increase vulnerability to local economic fluctuations.
- Xiangyu Medical's product range lacks international certifications for global market expansion.
Opportunities
- Growing demand for rehabilitation equipment in China's aging population presents significant market opportunities.
- Expansion into postpartum and cardiopulmonary rehabilitation fields could increase market share.
- Partnerships with domestic healthcare providers may enhance product adoption and market reach.
Threats
- Intense competition from domestic healthcare equipment manufacturers threatens market share.
- Economic downturns in China could reduce healthcare spending and impact sales.
- Regulatory changes in the Chinese healthcare sector may increase operational costs.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.